Unraveling p300/CBP oncogenic signaling utilizing small molecule inhibitors and probes

利用小分子抑制剂和探针揭示 p300/CBP 致癌信号传导

• 批准号: 276707199
• 负责人: Dr. André Richters
• 金额: --
• 依托单位: Forschungsgebiet Chemische Biologie
• 依托单位国家: 德国
• 项目类别: Research Fellowships
• 财政年份: 2015
• 资助国家: 德国
• 起止时间: 2014-12-31 至 2016-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/276707199?language=en
• 关键词: Unraveling; p300; CBP; oncogenic; signaling

This research proposal aims to develop a robust and cost-efficient biochemical assay to identify inhibitors and ligands for the histone acetyltransferases (HATs) p300 and CBP. Furthermore, high throughput screens using chemically diverse compound libraries will be performed in an effort to identify potent small molecule HAT inhibitors. The ultimate goal is to develop effective and specific HAT inhibitors and tool compounds to probe their potential to inhibit the biological activity of p300/CBP target oncogenes by affecting their stability and inducing their enhanced degradation. In particular, it is desired to discover ligands which may disrupt the HAT-mediated c-Myc activation in order to decipher the oncogenic interactions within the c-Myc interactome using multiple cancer cell lines (e.g., prostate cancer and melanoma). If applicable further investigations with respect to the potential use of these molecules as anticancer agents in animal models are intended. This research approach will also investigate the potential use of HAT inhibitors in inhibiting other acetylation-dependent oncogenic transcription factors such as androgen and estrogen receptors, which can lead to broad applications in cancer research.This research has the potential to uncover small molecule p300/CBP inhibitors to further understand the biological impact of HAT activity in tumor development as well as in understanding the role of acetylation in the tumorigenicity of known transcription factor oncogenes.

该研究计划旨在开发一种稳健且具有成本效益的生化检测方法，以识别组蛋白乙酰转移酶（HAT）p300和CBP的抑制剂和配体。此外，将使用化学上不同的化合物文库进行高通量筛选，以鉴定有效的小分子HAT抑制剂。最终目标是开发有效和特异性的HAT抑制剂和工具化合物，以探索其通过影响其稳定性和诱导其增强降解来抑制p300/CBP靶癌基因的生物活性的潜力。特别地，希望发现可以破坏HAT介导的c-Myc活化的配体，以便使用多种癌细胞系（例如，前列腺癌和黑色素瘤）。如适用，计划进一步研究这些分子在动物模型中作为抗癌剂的潜在用途。该研究方法还将研究HAT抑制剂在抑制其他乙酰化依赖性致癌转录因子如雄激素和雌激素受体方面的潜在用途，这项研究有可能揭示小分子p300/CBP抑制剂，以进一步了解HAT活性在肿瘤发展中的生物学影响，以及了解乙酰化在已知转录因子致癌基因的致瘤性。